$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000161883518000105 Filed on November 07, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.210M	$8.580M	$1.330M
YoY Change	157.92%	545.11%	46.15%
% of Gross Profit
Research & Development	$9.770M	$9.851M	$6.263M
YoY Change	2691.43%	57.29%	552.4%
% of Gross Profit
Depreciation & Amortization	$60.00K	$70.00K	$10.00K
YoY Change	200.0%	600.0%	0.0%
% of Gross Profit
Operating Expenses	$14.98M	$18.43M	$9.070M
YoY Change	-2.38%	103.23%	385.03%
Operating Profit		-$18.43M	-$9.070M
YoY Change		103.23%
Interest Expense	$30.00K	$40.00K	$10.00K
YoY Change	200.0%	300.0%	-102.04%
% of Operating Profit
Other Income/Expense, Net	$0.00	$2.000K	$64.96M
YoY Change	-100.0%	-100.0%
Pretax Income	-$14.98M	-$18.43M	-$74.03M
YoY Change	534.75%	-75.1%	3036.91%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$14.98M	-$18.43M	-$74.03M
YoY Change	-23.15%	-75.1%	3036.91%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$579.3K	-$714.9K	-$783.5K
COMMON SHARES
Basic Shares Outstanding	25.87M shares	25.80M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.300M	$12.10M	$5.800M
YoY Change	-61.76%	108.62%	-59.72%
Cash & Equivalents	$1.330M	$12.08M	$3.660M
Short-Term Investments
Other Short-Term Assets	$700.0K	$1.000M	$400.0K
YoY Change	16.67%	150.0%	-20.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$2.478M	$13.42M	$6.100M
YoY Change	5.27%	120.07%	-59.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$593.0K	$652.0K	$0.00
YoY Change	-30.07%		-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$939.0K	$950.0K	$100.0K
YoY Change	25.2%	850.0%	-50.0%
Total Long-Term Assets	$1.532M	$1.602M	$100.0K
YoY Change	-4.13%	1502.0%	-66.67%
TOTAL ASSETS
Total Short-Term Assets	$2.478M	$13.42M	$6.100M
Total Long-Term Assets	$1.532M	$1.602M	$100.0K
Total Assets	$4.010M	$15.03M	$6.200M
YoY Change	1.47%	142.35%	-59.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.882M	$8.034M	$400.0K
YoY Change	-1.3%	1908.5%	-50.0%
Accrued Expenses	$11.51M	$14.45M	$1.000M
YoY Change	-4.74%	1344.7%	66.67%
Deferred Revenue
YoY Change
Short-Term Debt	$4.000M	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.33M	$25.04M	$1.400M
YoY Change	-73.56%	1688.71%	0.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00
YoY Change	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.33M	$25.04M	$1.400M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$27.37M	$25.09M	$1.400M
YoY Change	-73.59%	1692.21%	0.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$433.1M	-$418.2M
YoY Change	40.96%
Common Stock	$409.8M	$408.1M
YoY Change	2211.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$23.36M	-$10.07M	$4.800M
YoY Change
Total Liabilities & Shareholders Equity	$4.010M	$15.03M	$6.200M
YoY Change	1.47%	142.35%	-59.23%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$14.98M	-$18.43M	-$74.03M
YoY Change	-23.15%	-75.1%	3036.91%
Depreciation, Depletion And Amortization	$60.00K	$70.00K	$10.00K
YoY Change	200.0%	600.0%	0.0%
Cash From Operating Activities	-$10.25M	-$8.920M	-$1.840M
YoY Change	334.32%	384.78%	-41.21%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$10.00K	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-500.0K	-1.900M	0.000
YoY Change	-1766.67%		-100.0%
NET CHANGE
Cash From Operating Activities	-10.25M	-8.920M	-1.840M
Cash From Investing Activities	-10.00K	0.000	0.000
Cash From Financing Activities	-500.0K	-1.900M	0.000
Net Change In Cash	-10.76M	-10.82M	-1.840M
YoY Change	361.8%	488.04%	-74.16%
FREE CASH FLOW
Cash From Operating Activities	-$10.25M	-$8.920M	-$1.840M
Capital Expenditures	-$10.00K	$0.00
Free Cash Flow	-$10.24M	-$8.920M
YoY Change	333.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	evfm	Accrued Deferred Offering Costs Current AccruedDeferredOfferingCostsCurrent	135000	USD
CY2018Q3	evfm	Accrued Deferred Offering Costs Current AccruedDeferredOfferingCostsCurrent	132000	USD
CY2017Q4	evfm	Accrued Directors Fees And Related Expenses Current AccruedDirectorsFeesAndRelatedExpensesCurrent	247000	USD
CY2018Q3	evfm	Accrued Directors Fees And Related Expenses Current AccruedDirectorsFeesAndRelatedExpensesCurrent	50000	USD
CY2017Q4	evfm	Accrued Interest Unpaid Sublicense Fees AccruedInterestUnpaidSublicenseFees	76000	USD
CY2018Q3	evfm	Accrued Interest Unpaid Sublicense Fees AccruedInterestUnpaidSublicenseFees	154000	USD
CY2017Q4	evfm	Accrued Sublicense Fees AccruedSublicenseFees	2000000	USD
CY2018Q3	evfm	Accrued Sublicense Fees AccruedSublicenseFees	1117000	USD
CY2018Q2	evfm	Class Of Warrant Or Right Issued In Transaction ClassOfWarrantOrRightIssuedInTransaction	8500000	shares
	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
CY2017Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	8789000	USD
CY2018Q3	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	12499000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25867248	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	evfm	Deemed Contribution Upon Exchange Of Preferred Stock DeemedContributionUponExchangeOfPreferredStock	49334000	USD
	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	152000	USD
	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	536000	USD
	evfm	Deferred Rent Adjustment DeferredRentAdjustment	20000	USD
	evfm	Deferred Rent Adjustment DeferredRentAdjustment	229000	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Annual Principal Payment DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableAnnualPrincipalPayment	300000	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Stated Rate DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableStatedRate	0.05
CY2017Q1	evfm	Early Lease Termination Fees EarlyLeaseTerminationFees	55000	USD
	evfm	Gain Loss On Issuance Of Convertible Preferred Stock GainLossOnIssuanceOfConvertiblePreferredStock	0	USD
	evfm	Gain Loss On Issuance Of Convertible Preferred Stock GainLossOnIssuanceOfConvertiblePreferredStock	-47920000	USD
	evfm	Issuance Of Temporary Equity Liquidation Preference IssuanceOfTemporaryEquityLiquidationPreference	2769000	USD
	evfm	Issuance Of Temporary Equity Liquidation Preference IssuanceOfTemporaryEquityLiquidationPreference	0	USD
CY2015Q1	evfm	Lessee Operating Lease Renewal Term1 LesseeOperatingLeaseRenewalTerm1	P5Y
CY2017Q3	evfm	Loss On Issuance Of Redeemable Convertible Preferred Stock And Related Warrants Net LossOnIssuanceOfRedeemableConvertiblePreferredStockAndRelatedWarrantsNet	5740000	USD
	evfm	Loss On Issuance Of Redeemable Convertible Preferred Stock And Related Warrants Net LossOnIssuanceOfRedeemableConvertiblePreferredStockAndRelatedWarrantsNet	5740000	USD
CY2018Q3	evfm	Loss On Issuance Of Redeemable Convertible Preferred Stock And Related Warrants Net LossOnIssuanceOfRedeemableConvertiblePreferredStockAndRelatedWarrantsNet	0	USD
	evfm	Loss On Issuance Of Redeemable Convertible Preferred Stock And Related Warrants Net LossOnIssuanceOfRedeemableConvertiblePreferredStockAndRelatedWarrantsNet	0	USD
CY2017Q3	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
CY2018Q3	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
CY2018Q3	evfm	Operating Leases Future Minimum Net Payments Due Current OperatingLeasesFutureMinimumNetPaymentsDueCurrent	150000	USD
	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	47920000	USD
CY2018Q3	evfm	Operating Leases Future Minimum Net Payments Due OperatingLeasesFutureMinimumNetPaymentsDue	932000	USD
CY2018Q3	evfm	Operating Leases Future Minimum Net Payments Due In Three Years OperatingLeasesFutureMinimumNetPaymentsDueInThreeYears	161000	USD
CY2018Q3	evfm	Operating Leases Future Minimum Net Payments Due In Two Years OperatingLeasesFutureMinimumNetPaymentsDueInTwoYears	621000	USD
CY2018Q3	evfm	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Current OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsCurrent	37000	USD
CY2018Q3	evfm	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Due In Three Years OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueInThreeYears	40000	USD
CY2018Q3	evfm	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Due In Two Years OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueInTwoYears	155000	USD
	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	37542000	USD
CY2014Q4	evfm	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized	0.010
	evfm	Stock And Warrants Issued During Period Value StockAndWarrantsIssuedDuringPeriodValue	36030000	USD
	evfm	Warrants And Stock Issued During Period Value New Issues WarrantsAndStockIssuedDuringPeriodValueNewIssues	14062000	USD
CY2018Q3	evfm	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	-11600000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8999000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	8034000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12086000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14447000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	727000	USD
CY2018Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	275000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	342000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	538000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17731000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	408097000	USD
	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-1526000	USD
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	80000000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16086000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	216000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	647000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4735000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16086000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7761207	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9414210	shares
CY2017Q4	us-gaap	Assets Assets	3952000	USD
CY2018Q3	us-gaap	Assets Assets	15026000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	2354000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	13424000	USD
CY2018Q3	us-gaap	Cash Cash	12100000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1900000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3660000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1211000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12076000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4165000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12522000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11487000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4165000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1701000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12522000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7322000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	10821000	USD
CY2018Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.30
CY2018Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3142000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	1900000	USD
CY2018Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9613123	shares
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	11875	shares
CY2018Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4775886	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4051137	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2082053	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25884625	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2082053	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25884625	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2017Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	80	shares
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	114000	USD
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	49000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	179000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	196000	USD
CY2018Q3	us-gaap	Depreciation Nonproduction DepreciationNonproduction	65000	USD
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	200000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	79870000	USD
CY2018Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1300000	USD
CY2017Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	5200000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-38.31
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-45.23
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.38
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2392000	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2561000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2807000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8018000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8582000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29018000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-74031000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-85809000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18431000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-110729000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-130000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	46000	USD
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-59811000	USD
CY2018Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-64961000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1501000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1447000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2139000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	435000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-56000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-138000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	207000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	32000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	95000	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	35000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	97000	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	500000	USD
CY2018Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	500000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	103627000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	25091000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3952000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15026000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	103347000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	25042000	USD
CY2017Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-59211000	USD
CY2017Q4	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2018Q3	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6727000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54924000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	244000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2150000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14293000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46253000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-74031000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-85812000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-18431000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-110731000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75085000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-88651000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18431000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-110797000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-65468000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-115000	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	200000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	157000	USD
CY2018Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-33000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-48068000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	9070000	USD
	us-gaap	Operating Expenses OperatingExpenses	20341000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	18433000	USD
	us-gaap	Operating Expenses OperatingExpenses	62661000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9070000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20341000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18433000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-62661000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1164000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	187000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals	232000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	201000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	776000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	112000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	220000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	750000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	950000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	166000	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-42000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	698000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	977000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1526000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	653000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	902000	USD
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	7425000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	20000000	USD
CY2016Q3	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	600000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1190000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1190000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	848000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9851000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	652000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6263000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12323000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.909
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.886
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.869
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.022
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33643000	USD
CY2017Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	490000	USD
CY2018Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	446000	USD
CY2017Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	505000	USD
CY2018Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	446000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-307277000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-418165000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-418200000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	647000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	16086000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.029
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.028
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate	0.15
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	28333	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7928	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1147895	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4418300	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M12D
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2017Q3	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2018Q3	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2018Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	605114	shares
	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	5226000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	121315000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-289546000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	-10065000	USD
	us-gaap	Stockholders Equity Change In Reporting Entity StockholdersEquityChangeInReportingEntity	1946000	USD
CY2018Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	166.7000
	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	223000	USD
CY2017Q3	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	1054000	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	2839000	USD
CY2018Q3	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	66000	USD
CY2018Q1	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	14100000	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1959904	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1959904	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25778316	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20580017	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking and time deposit accounts are maintained in federally insured financial institutions in excess of federally insured limits. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances due to the financial position of the depository institutions in which these deposits are held.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes thereto.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On an ongoing basis, management evaluates its estimates related to, but not limited to, the useful lives of property and equipment, the recoverability of long-lived assets, preclinical and clinical trial accruals, the measurement of the Series D 2X liquidation preference, assumptions used in estimating the fair value of warrants issued in connection with the Merger, assumptions used in estimating the fair value of stock-based compensation expense and other contingencies. The Company’s assumptions regarding the measurement of the Series D 2X liquidation preference and stock-based compensation are more fully described in </font><a style="font-family:inherit;font-size:10pt;" href="#sDDC9DAA3FC3F5DF5AAA45685368A0E96"><font style="font-family:inherit;font-size:10pt;">Note 5 — Fair Value of Financial Instruments</font></a><font style="font-family:inherit;font-size:10pt;"> and </font><a style="font-family:inherit;font-size:10pt;" href="#s2F6C6BF6889D5B63BC1DE4BEE3D94B27"><font style="font-family:inherit;font-size:10pt;">Note 11 — Stock-based Compensation, </font></a><font style="font-family:inherit;font-size:10pt;">respectively. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001618835-18-000105-index-headers.html	Edgar Link	pending
0001618835-18-000105-index.html	Edgar Link	pending
0001618835-18-000105.txt	Edgar Link	pending
0001618835-18-000105-xbrl.zip	Edgar Link	pending
evfm-20180930.xml	Edgar Link	completed
evfm-20180930.xsd	Edgar Link	pending
evfm-20180930_cal.xml	Edgar Link	unprocessable
evfm-20180930_def.xml	Edgar Link	unprocessable
evfm-20180930_lab.xml	Edgar Link	unprocessable
evfm-20180930_pre.xml	Edgar Link	unprocessable
evfm-930201810xq.htm	Edgar Link	pending
evfm-9302018ex311.htm	Edgar Link	pending
evfm-9302018ex312.htm	Edgar Link	pending
evfm-9302018ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2018 Q4 Form 10-Q Financial Statement

#000161883518000105 Filed on November 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2018 Q4 Form 10-Q Financial Statement

#000161883518000105 Filed on November 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm